Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 21

Nasal spray with gold nanoparticles delivers targeted treatment to the brain

Tiny gold particles that act as carriers for lithium can be delivered directly to the brain in the form of a nasal spray. Developed by scientists at the Università Cattolica Rome campus/Fondazione Policlinico Universitario A. Gemelli IRCCS, the new nanotechnological device can be used for the treatment and prevention of neuropsychiatric and neurodegenerative diseases.

Lithium is already in for manic-depressive syndrome, but in oral formulation it is not free of side effects. It is used to combat neuropsychiatric diseases such as bipolar disorder, neurodegenerative diseases such as Alzheimer’s disease, and brain infections such as those caused by Herpes Simplex Virus type 1, which several recent studies have linked to an increased risk of neurological diseases.

Published in the journal Advanced Materials and already patented, the idea is the result of a study that demonstrated that it is possible to directly inhibit the activity of an enzyme that plays a key role in the development of these diseases (glycogen synthase kinase-3 beta, GSK-3β) directly in the brain by using lithium delivered by intranasally administered .

From trips to treatments: how psychedelics could revolutionise anti-inflammatory medicine

Once synonymous with hippies and hallucinatory experiences, psychedelic drugs are now being explored for their medical potential. The stigma of that era resulted in research being suppressed by drug laws, yet with mental health treatments hitting limits, scientists have returned to this controversial corner of medicine.

Substances like psilocybin (found in magic mushrooms) and ayahuasca are now being taken seriously by scientists and doctors, not for the visions they induce, but for the healing potential they possess.

Initially, this focused on treating mental health conditions like depression, where currently prescribed drugs only help a minority of patients. But these investigations have now expanded to include diseases driven by inflammation, which psychedelic drugs may help reduce by calming down the immune system.

Magic mushrooms and LSD may do more than bend minds: they could fight inflammation linked to depression, arthritis and heart disease.

For the first time, scientists pinpoint brain cells linked to depression

Scientists identified two types of brain cells, neurons and microglia, that are altered in people with depression. Through genomic mapping of post-mortem brain tissue, they found major differences in gene activity affecting mood and inflammation. The findings reinforce that depression has a clear biological foundation and open new doors for treatment development.

Scientists create nanofluidic chip with ‘brain-like’ memory pathways

Scientists at Monash University have created a tiny fluid-based chip that behaves like neural pathways of the brain, potentially opening the door to a new generation of computers.

Roughly the size of a coin, the chip was built from a specially designed metal-organic framework (MOF), and channels ions through tiny pathways, mimicking the on/off switching of electronic transistors in computers.

But unlike conventional computer chips, it can also “remember” previous signals, mimicking the plasticity of neurons in the brain.

Receptor in cerebellum provides new insights into molecular basis of ataxia

Researchers at Ruhr University Bochum, Germany, identified a receptor that plays a crucial role in stress-induced motor incoordination associated with ataxias. These hereditary motor disorders have long been linked to the neurotransmitter norepinephrine.

The team, led by Dr. Pauline Bohne and Professor Melanie Mark from the Behavioral Neurobiology Working Group in Bochum, has now shown that the α1D norepinephrine receptor in the cerebellum is responsible for the symptoms. The team published these findings in the journal Cellular and Molecular Life Sciences on October 6, 2025.

People with experience recurring episodes of motor incoordination, also known as dystonia. These phases are triggered by various factors, such as physical or , fever, alcohol, or caffeine. The episodes are triggered by the release of norepinephrine in the cerebellum, which is the most important brain region for coordinating movement. Currently, there is no cure for ataxia. Therefore, researchers want to gain a better understanding of the underlying mechanisms to find new treatment approaches.

Scientists discover brain circuit that can switch off chronic pain

Scientists have pinpointed Y1 receptor neurons in the brain that can override chronic pain signals when survival instincts like hunger or fear take precedence. Acting like a neural switchboard, these cells balance pain with other biological needs. The research could pave the way for personalized treatments that target pain at its brain source—offering hope for millions living with long-term pain.

Schizophrenia is linked to iron and myelin deficits in the brain, neuroimaging study finds

Schizophrenia is a severe and debilitating psychiatric disorder characterized by hallucinations, disorganized speech and thought patterns, false beliefs about the world or oneself, difficulties concentrating and other symptoms impacting people’s daily functioning. While schizophrenia has been the topic of numerous research studies, its biological and neural underpinnings have not yet been fully elucidated.

While some past brain imaging studies suggest that is associated with abnormal levels of and in the brain, the results collected so far are conflicting. Iron is a metal known to contribute to healthy brain function, while myelin is a fatty substance that forms a sheath around nerve fibers, protecting them and supporting their conduction of electrical signals.

Researchers at King’s College London, Hammersmith Hospital and Imperial College London recently set out to further explore the possibility that schizophrenia is linked to abnormal levels of iron and myelin in the brain. Their findings, published in Molecular Psychiatry, uncovered potential new biomarkers of schizophrenia that could improve the understanding of its underlying brain mechanisms.

/* */